Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258557 | 1.00 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKCD274JAK3 | |
| SCHEMBL7264298 | 1.00 | GRIN2B (0.37) | GRIN2BGRIN2CCTSKCD274JAK3 | |
| SCHEMBL5135426 | 0.87 | GRIN2B (0.38) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL1949227 | 0.87 | GRIN2B (0.35) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL14282561 | 0.87 | GRIN2B (0.35) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL14282367 | 0.84 | GRIN2B (0.33) | GRIN2BGRIN2CCTSKJAK3 | |
| SCHEMBL4569940 | 0.84 | GRIN2B (0.38) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL19614453 | 0.83 | GRIN2B (0.39) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL15924562 | 0.83 | GRIN2B (0.39) | GRIN2BGRIN2CCTSKJAK3USP2 | |
| SCHEMBL19614479 | 0.83 | GRIN2B (0.39) | GRIN2BGRIN2CCTSKJAK3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121021362-A | Synthesis method of (R) -N-tert-butoxycarbonyl-alpha-allylproline | 四川同晟生物医药有限公司 | 2025-11-28 | — | — | CN | disclosed |
| CN-121021362-A | Synthesis method of (R) -N-tert-butoxycarbonyl-alpha-allylproline | 四川同晟生物医药有限公司 | 2025-11-28 | — | — | CN | disclosed |
| WO-2013148537-A1 | SUBSTITUTED SPIROBICYCLIC COMPOUNDS AND METHODS OF USE | XI NING (US) | 2013-10-03 | — | — | WO | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-20100029736-A1 | 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029736-A1 | 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-1294747-B1 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR SA (ES) | 2008-04-30 | — | — | EP | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| EP-1332134-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002060868-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | GRIN2B 2925/4885GRIN2C 3786/4885CTSK 3079/4885 |
| US-20100029736-A1 | 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | GRIN2B 71/4885GRIN2C 51/4885CTSK 1195/4885 |
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | MYD88, TLR4, TLR6 | GRIN2B 2563/4885GRIN2C 3043/4885CTSK 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.